Pharmacological Prevention of Atrial Fibrillation after Cardiac Surgery with and without the Use of Nonsteroidal Anti-inflammatory Drugs by Neubauer, Laura et al.
Baptist Health South Florida 
Scholarly Commons @ Baptist Health South Florida 
All Publications 
5-2020 
Pharmacological Prevention of Atrial Fibrillation after Cardiac 
Surgery with and without the Use of Nonsteroidal Anti-
inflammatory Drugs 
Laura Neubauer 
Baptist Hospital of Miami, LauraNeu@baptisthealth.net 
Radhan Gopalani 
Baptist Hospital of Miami, radhang@baptisthealth.net 
Faaria Quadri 
Baptist Hospital of Miami, FaariaQ@baptisthealth.net 
Mario Pascual 
Baptist Health Medical Group; Miami Cardiac & Vascular Institute, MarioPa@baptisthealth.net 
Heidi Clarke 
Baptist Hospital of Miami, heidic@baptisthealth.net 
See next page for additional authors 
Follow this and additional works at: https://scholarlycommons.baptisthealth.net/se-all-publications 
 Part of the Cardiology Commons, Chemicals and Drugs Commons, and the Pharmacy and 
Pharmaceutical Sciences Commons 
Citation 
Neubauer, Laura; Gopalani, Radhan; Quadri, Faaria; Pascual, Mario; Clarke, Heidi; and Marr-Peralto, Andrea, 
"Pharmacological Prevention of Atrial Fibrillation after Cardiac Surgery with and without the Use of 
Nonsteroidal Anti-inflammatory Drugs" (2020). All Publications. 3527. 
https://scholarlycommons.baptisthealth.net/se-all-publications/3527 
This Conference Lecture -- Open Access is brought to you for free and open access by Scholarly Commons @ 
Baptist Health South Florida. It has been accepted for inclusion in All Publications by an authorized administrator 
of Scholarly Commons @ Baptist Health South Florida. For more information, please contact 
Carrief@baptisthealth.net. 
Authors 
Laura Neubauer, Radhan Gopalani, Faaria Quadri, Mario Pascual, Heidi Clarke, and Andrea Marr-Peralto 
This conference lecture -- open access is available at Scholarly Commons @ Baptist Health South Florida: 
https://scholarlycommons.baptisthealth.net/se-all-publications/3527 
Pharmacological Prevention of Atrial Fibrillation After 
Cardiac Surgery With and Without the Use of Nonsteroidal 
Anti-inflammatory Drugs 
Laura Neubauer, Pharm.D., PGY-1 Pharmacy Resident 
Baptist Hospital of Miami
Longitudinal Research Project
Disclosures
The following contributors have nothing to disclose regarding any financial or nonfinancial 
relationships with the products described, reviewed, or evaluated in this presentation: 
 Laura Neubauer, Pharm.D. 
 Radhan Gopalani, Pharm.D., BCPS 
 Faaria Quadri, Pharm.D., BCPS
 Heidi Clarke, Pharm.D., BCCCP
 Mario Ignacio Pascual, M.D.
 Andrea-Marr Peralto, DNP,  AGACNP,  APRN
 Cathleen Charles, MSN,  APRN,  FNP-BC
Abbreviations
ACC/AHA/HRS: American College of Cardiology/American 
Heart Association/Heart Rhythm Society
AF: Atrial Fibrillation 
AFACS:  Atrial Fibrillation After Cardiac Surgery
AKI:  Acute Kidney Injury 
AVR:  Aortic Valve Replacement 
BHM: Baptist Hospital of Miami 
BHSF: Baptist Health South Florida  
CABG: Coronary Artery Bypass Graft
CKD: Chronic Kidney Disease
COPD: Chronic Obstructive Pulmonary Disease
ICU: Intensive Care Unit
HFrEF: Heart Failure with a reduced Ejection Fraction
LA: Left Atrium
LOS: Length of Stay  
LV: Left Ventricle
LVEF: Left Ventricular Ejection Fraction
MVR: Mitral Valve Replacement 
NSAIDs: Nonsteroidal Anti-Inflammatory Drugs
PMH: Past Medical History
SCA/EACTA: Society of Cardiovascular Anesthesiologists /  
European Association of Cardiothoracic Anesthesiology 
SD: Standard Deviation
SMH: South Miami Hospital
Tx: Treatment 
Presentation Objective 
Discuss the impact of NSAID use on the incidence of atrial 
fibrillation and acute kidney injury in cardiac surgery patients 
Background 
 Post-operative atrial fibrillation is the most 
common complication following cardiac surgery 
 25% following CABG 
 30% following valvular surgery 
 40-50% following CABG/valvular procedures 
 AFACS is associated with 
 ↑ Morbidity – stroke, infection, GI/renal dysfunction
 ↑ Mortality 
 ↑ LOS (ICU and hospital) 
 ↑ Financial burden 
 ↑ Readmission rates 
Burrage PS. Current Anesthesiology Reports. 2019;9:174-193.
Dobrev D. Nat. Rev. Cardiol. 2019;16:417-436. 
Muehlschlegel JD. Anesth Analg. 2019;128(1):33–42. 
Risk Factors for AFACS 
↑Age  
(> 75yo) 
History 
of AF
Obesity COPD HFrEF
Chronic 
renal 
failure 
Male 
gender  
On-
pump 
surgery
LV 
hypertrophy
Burrage PS.  Current Anesthesiology Reports. 2019;9:174-193. 
Muehlschlegel JD. Anesth Analg. 2019;128(1):33–42. 
Guideline 
Recommendations 
for β-blockers
and Amiodarone as 
AF Prophylaxis
2014
ACC/AHA/HRS Guidelines
•β-blockers = Class Ia recommendation
•Amiodarone = Class IIa recommendation
2014
AATS Guidelines 
•β-blockers = Class Ia recommendation
•Amiodarone = Class IIa recommendation
2016
ESC Guidelines 
•β-blockers = Class Ib recommendation
•Amiodarone = Class IIa recommendation
2019
SCA/EACTA Guidelines 
•β-blockers = Class Ia/b recommendation
•Amiodarone = Class IIa/b recommendation
January CT. J Am Coll Cardiol. 2014;64(21):2246-80.
Kirchhof P. Rev Esp Cardiol (Engl Ed). 2017;70(1):50.
Muehlschlegel JD. Anesth Analg. 2019;128(1):33–42. 
Frendyl G. J Thorac Cardiovasc Surg. 2014;148(3):153-193.
Literature Regarding NSAID Use 
Efficacy of Nonsteroidal Anti‐Inflammatory 
Medications for Prevention of Atrial Fibrillation 
Following Coronary Artery Bypass Graft Surgery 
(2004)
• Primary Outcome: Incidence of atrial fibrillation in the 
immediate postoperative period (7 days post-op or until discharge, 
whichever came first)
• Study Groups:
•Experimental Group: IV ketorolac (30mg IV q6g x 48h) followed 
by PO ibuprofen (600mg PO TID x 7d)
•Control Group: Placebo 
• Results: Incidence of AFACS was significantly lower in the group 
that received NSAIDs compared to placebo (9.8% vs 28.6%, 
p=0.017), with no significant difference in renal failure 
Cheruku KK,. Prev Cardiol. 2004;7(1):13-18.
Literature Regarding NSAID Use 
Naproxen as Prophylaxis against Atrial Fibrillation after Cardiac Surgery: The NAFARM Randomized Trial (2011)
Experimental 
Group
Naproxen 275 mg 
PO q12h x 5d
Primary 
Outcome
Occurrence of atrial 
fibrillation in the first 
5 postoperative days  
Control Group
Placebo
Results
No significant 
difference in AFACS 
(7.3% vs 15.2%, p=0.11)
Naproxen group
• ↓ duration of AF 
(0.35h vs 3.74h, p=0.04)
• ↑ in renal failure
(7.3% vs 1.3%, p=0.06)
Horbach SJ. Am J Med. 2011;124(11):1036-42. 
2017 Study at BHM 
 In 2017, a study done at BHM showed that incidence of AFACS decreased from 36% to 22% following 
implementation of a prevention protocol that included metoprolol, amiodarone and NSAIDs
 The following protocol was implemented across BHSF hospitals:
While Intubated Post Extubation 
Amiodarone 
150 mg IV bolus followed by infusion at 
1 mg/min x 6 hours  0.5 mg/min x 18 hours
600 mg PO BID x 5d
(cont infusion drip with PO if 24h infusion 
incomplete at the time of extubation) 
Metoprolol tartrate 
5 mg IV q6h 
(hold if SBP < 100, HR < 60 or if currently paced via 
epicardial wires) 
25 mg PO BID, or 50 mg PO BID, or 75 mg PO BID
(Hold for SBP < 100, or HR < 60)
NSAID
Ketorolac 30 mg IV q6h x 48 hours (or while intubated)
(CrCl 25-50 mL/min, use 15 mg IV q6h; do not use if pt 
is actively bleeding or CrCl < 25 mL/min)
Ibuprofen 600 mg PO TID x 7d
(Do not give if CrCl < 30 mL/min)
Current Practices at BHM and SMH 
 Considerations regarding current AFACS prevention protocol: 
 Potential increase in AKI/renal failure due to around the clock administration of NSAIDs 
 Inherent risk of AKI in ~35% of patients after cardiac surgery; increases postoperative mortality 
rates to over 60%
 At both BHM and SMH, these risks have prompted healthcare providers 
to avoid the use of NSAIDs post-cardiac surgery
Research Purpose
To assess if NSAIDs affect patient outcomes 
when they are used to prevent AFACS
Study Design 
Retrospective chart review of patients who underwent an open-heart 
procedure (CABG, MVR, AVR, double valve replacement, combination 
CABG/valvular replacement surgery, aortic surgery) at either BHM or 
SMH and received pharmacological prophylaxis to prevent AFACS 
Study Population: 
 Cohort A (NSAIDs):  metoprolol, amiodarone and NSAIDs
 Cohort B (No NSAIDs):  metoprolol and amiodarone 
Eligibility Criteria
• Adult patients (> 18 years old) 
• Underwent one of the following cardiac surgeries: 
CABG, MVR,  AVR, Double valve replacement,  
combination CABG/valvular,  Aortic Surgery
• Underwent cardiac surgery between 5/1/2019 and 
12/20/2019 
• Received at least one of the protocol medications
Inclusion Criteria Exclusion Criteria 
• Patients who are pregnant
• Patients who are incarcerated
Data Collection 
Method
 All patients who underwent open-heart surgery at either 
BHM or SMH between 5/1/2019 and 12/20/2019 were 
screened for inclusion/exclusion criteria 
 On screening, patients were separated into Cohort A or 
Cohort B based on prophylactic therapy received 
 Cohort A (NSAIDs): 3 drugs (metoprolol, amiodarone and NSAIDs)
 Cohort B (No NSAIDs): 2 drugs (metoprolol and amiodarone)
Study Outcomes 
Incidence of new-onset AFACS within the first 7 days after surgery
• Postoperative incidence of AKI (↑ in Scr > 0.3 mg/dL in 48h or ↑ in
S Scr to >1.5x baseline in 7 days)
• ICU length of stay (days) 
• Hospital length of stay (days)
10
20
Results
Patient Selection
215 pts 
screened
198 pts included
19 pts received one 
protocol medication
12 pts received only 
Amiodarone
7 pts received only a 
beta-blocker
16 pts received meds 
as tx for AF
163 pts analyzed Cohort A (NSAIDS) 
(n=76)
Cohort B (No NSAIDs) 
(n=87)17 pts excluded
Reason for Exclusion n=17
Did not receive prophylactic therapy for AFACS 8
Surgery performed outside of study period 9
Demographics and Baseline Characteristics 
NSAIDs
n=76
No NSAIDs 
n=87
p-value
Mean age, years (SD) 62 + 9 65 + 10.5 0.07
Age > 75 years – n (%) 6 (7.9) 17 (19.5) 0.03
Gender – male, n (%) 62 (81.6) 65 (74.7) 0.29
BMI (kg/m2) 
• 18.5 – 24 
• 25 - 30
• > 31 
9 (11.8)
31 (40.8)
36 (47.4)
22 (25.3)
28 (32.2)
37 (42.5)
0.03
0.25
0.54
Hospital
• BHM
• SMH
64 (84.2)
12 (15.8)
70 (80.5)
17 (19.5)
0.53
0.53
CABG – n (%)
• CABG x1
• CABG x2
• CABG x3
• CABG x4
63 (82.9)
13 (17.1)
23 (30.3)
23 (30.3)
4 (5.3)
73 (83.9)
8 (9.2)
24 (27.6)
30 (34.5)
11 (12.6)
0.86
0.12
0.66
0.58
0.11
Valvular Surgery – n (%)
• AVR
• MVR
12 (15.8)
10 (13.2)
2 (2.6)
11 (12.6)
10 (11.5)
1 (1.5)
0.56
0.59
0.59
CABG + Valvular Surgery – n (%) 1 (1.3) 1 (1.5) 0.92
NSAIDs
n=76
No NSAIDs 
n=87
p-value
PMH – n (%)
• Hypertension
• Hyperlipidemia 
• Type 2 Diabetes
• Hypothyroidism 
• Tobacco Use 
• Current
• Former
• Peripheral Artery Disease
• Myocardial Infarction
• Chronic Kidney Disease
• Stage I
• Stage II
• Stage III
• Stage IV
• Stage V
60 (78.9)
59 (77.6)
30 (39.5)
8 (10.5)
11 (14.5)
31 (40.8)
2 (2.6)
16 (21.1)
2 (2.6)
0
0
2
0
0
70 (80.5)
53 (60.9)
37 (42.5)
6 (6.9)
14 (16.1)
17 (19.5)
6 (6.9)
17 (19.5)
21 (24.1)
0
0
18
0
3
0.81
0.02
0.69
0.41
0.77
< 0.01
0.21
0.81
< 0.01
Baseline Scr – mean (SD) 0.94 + 0.23 1.5 + 1.8 < 0.01
Controlling for Confounding Factors
 To control for the disproportionate number of patients in Cohort B with renal 
dysfunction at baseline, patients with a PMH of CKD were removed from each 
cohort prior to analysis of the primary and secondary outcomes  
215 pts 
screened
198 pts included
19 pts received one 
protocol medication
12 pts received only 
Amiodarone
7 pts received only a 
beta-blocker16 pts received meds as 
tx for AF
163 pts analyzed Cohort A (NSAIDs) 
(n=76)
Cohort A (NSAIDs) 
(n=74)
Cohort B (No NSAIDs) 
(n=87)
Cohort B (No NSAIDs) 
(n=66)17 pts excluded
- 2
- 21
Risk Factors for AFACS 
Risk Factors NSAIDs (n=74) No NSAIDs (n=66) p-value
PMH of AF – n (%) 4 (5.4) 3 (4.5) 0.82
Reduced LVEF prior to surgery – n (%)
• LVEF 40-49% (mild dysfunction)
• LVEF 30-39% (moderate dysfunction)
• LVEF < 30% (severe dysfunction)
14 (18.9)
9 (12.2)
3 (4.1)
2 (2.7)
20 (30.3)
10 (15.2)
5 (7.6)
5 (7.6)
0.17
0.61
0.37
0.19
PMH of COPD – n (%) 3 (4.1) 1 (1.5) 0.37
PMH of coronary artery stenosis 62 (83.8) 57 (86.4) 0.67
Age > 75 years – n (%) 6 (8.1) 11 (16.7) 0.12
Type of procedure – n (%)
• On-pump
• Avg. time on cardiopulmonary bypass – hours (SD) 
• Off-pump
71 (95.9)
1:25 + 0:36
3 (4.1)
65 (98.5)
1:43 + 0:51
1 (1.5)
0.37
0.01
0.37
Hypotension requiring vasopressors post-op – n (%) 61 (82.4) 56 (84.8) 0.70
Study Outcomes 
12/74 
(16.2%)
10/66
(15.2%)
0
20
40
60
80
100
% Incidence of AFACS
%
 I
n
ci
d
e
n
ce
Incidence of new-onset AFACS 
NSAIDs (n=74) No NSAIDs (n=66)
NSAIDs 
(n=74)
No NSAIDs
(n=66)
p-value 
Incidence of AKI – n (%)
• Scr ↑ > 0.3 mg/dL in 48h or           
↑ > 1.5x baseline in 7d
• Scr ↑ > 0.3 mg/dL in 48h
• Scr ↑ > 1.5x baseline in 7d
15 (20.3)
12 (16.2)
7 (9.5)
17 (25.8)
12 (18.2)
12 (18.2)
0.44
0.76
0.13
Mean ICU length of stay, days (SD) 2.3 + 2.0 2.8 + 2.2 0.23
Mean hospital length of stay, days (SD) 10.6 + 6.1 11.0 + 4.6 0.63
10 Outcome 20 Outcomes
p-value= 0.86 
Study Outcomes – Incidence of AKI  
NSAIDs 
(n=74)
No NSAIDs 
(n=66)
p-value
Baseline Scr on admission – mean (SD) 0.92 + 0.2 1.1 + 0.4 < 0.01
Baseline Scr after surgery – mean (SD) 0.90 + 0.2 1.02 + 0.3 < 0.01
Maximum Scr after surgery – mean (SD) 1.07 + 0.3 1.30 + 0.5 < 0.01
# doses of NSAIDs postoperatively – mean (SD) 4.7 + 4.9 0 –
Postoperative hypotension requiring vasopressors – n (%)
• # vasopressors used – n (%) 
• 1 
• 2  
• 3 
• Mean # days on vasopressor therapy (SD)
61 (82.4)
33
28
0
1.7 + 0.8
57 (86.4)
20
25
12
2.0 + 1.0
0.52
0.08
0.99
< 0.01
0.06
Postoperative dehydration (BUN:Scr > 20:1) – n (%) 50 (67.6) 42 (63.6) 0.62
15/74
(20.3%)
12/74
(16.2%)
7/74
(9.5%)
17/66
(25.8%)
12/66
(18.2%)
12/66
(18.2%)
0
10
20
30
Scr ↑>0.3 in 48h or Scr 
↑>1.5x baseline in 7d
Scr ↑ >0.3 in 48h Scr ↑ >1.5x baseline in 
7d
%
 I
n
ci
d
e
n
ce
Incidence of Postoperative AKI
NSAIDs No NSAIDs
p = 0.44 p = 0.76 p = 0.13
Discussion
 There was no difference in the incidence of new-onset AFACS between cohorts (16.2% vs 15.2%, p=0.86)
 There was no difference in the incidence of AKI between cohorts (20.3% vs 25.8%, p=0.44)
 The numerically higher rates of AKI in patients who did not receive NSAIDs can be attributed to:
o Worse renal function at baseline 
o Higher requirement of vasopressor therapy post surgery 
 The difference in length of stay between cohorts was not statistically significant 
Limitations
1. Retrospective study design 
2. Small study population
 Anticipated ~100 patients in each cohort; only 163 patients met inclusion criteria, with 140 patients total being 
included in the final analysis
3. Selection bias 
 Patients with PMH of CKD were later removed from each cohort to control for this confounding factor
4. Confounding factors that could have impacted results in Cohort B
 Renal function at baseline
 Number of patients > 75 years old
 Postoperative hypotension requiring vasopressor therapy
 Duration of vasopressor therapy 
Conclusion
 When administered after an open-heart procedure, NSAIDs did not impact the 
incidence of postoperative atrial fibrillation, incidence of AKI or length of stay.  
 Given the risks of acute renal failure after cardiac surgery and the lack of benefit in 
the prevention of atrial fibrillation, these results support the removal of NSAIDs 
from the postoperative atrial fibrillation prevention protocol.
Self-Assessment Question
 The rationale for the inclusion of NSAIDs in an AFACS prevention protocol includes 
which of the following? 
A. Mild side effect profile
B. Pain relief
C. Anti-inflammatory effects
D. Low cost medications
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